© Fraunhofer IBMT.
Targeted transport of nanopackaged cytostatica in cancer cells.

Bioprocessing & Bioanalytics


Biomonitoring & Biobanks

  • planning, organization and management of sampling events of human and environmental samples
  • collection and documentation of medical history data, diary habits, life circumstances and lifestyle as well as further information on exposure relevant behaviour using standardized questionnaires
  • standardized analysis of clinical chemical parameters of human samples (blood, plasma, 24-hour urine collection)
  • biometrical characterization of human and environmental samples
  • development of protocols for biometrical sample characterization
  • sample preparation and cryopreservation
  • cryopreservation, cryostorage and administration of collected human and environmental samples
  • transport of samples under cryogenic conditions
  • statistical evaluation and interpretation of chemical and clinical data, data on body burden and medical history and biometrical data
  • elaboration and optimization of standard operating procedures (SOPs) according to ISO EN DIN/IEC 17025
  • operation of the cryo-repository of the German Environmental Specimen Bank (ESB) at Münster/Wolbeck
  • isolation and cultivation of adult stem cells of skin and inner organs of different animal species
  • characterization of adult stem cells of animal origin
  • cryopreservation and cryostorage of adult stem cells of animal origin

Cellular Bioprocessing

  • biobanking of microorganisms and clinical samples up to biological safety level (BSL) S3 according to genetic engineering act, infection protection act, biological agents regulations
  • production of bio-reagents (e. g. virus strains, GCLP-compliant)
  • optimization and validation of biological processes and technologies (up to certification in a quality management system)
  • cell cultivation
  • cell differentiation
  • automation of cell-based assays and processes (up to certification in a quality management system)
  • neutralization assays
  • immunoassays
  • optimization of cryoprocesses (e. g., cryo media and freezing procedures)
  • training (approx. 10 people)
    o general cell culture
    o automated cell culture
    o transfection of eukaryotic cells
    o working with infectious material
    • processing of peripheral mononuclear blood cells derived from whole blood
    • new methods of cryopreservation
    • vitality determination using flow cytometry
    • cell characterization using flow cytometry
    • measurement of immune responses (e. g. ELISpot)
    • bioluminescence assays
    • bacterial transformation
    • plasmid preparation
    • restriction digest
    • cloning
    • agarose gel electrophoresis
    • detection and analysis of proteins using Western Blot
    • introduction to quality assurance programs (e. g. Good Clinical Laboratory Practice – GCLP)
    • compilation of SOPs

Preclinical Nanomedicine

Preclinical testing of nanoparticular formulations

  • Examination of the interaction of nanomaterials with and crossing of biological barriers (e. g. blood-brain-barrier, intestinal barrier, skin and lung barrier) from primary and stem cells
    • measurement of transendothelial electrical resistance (TER) using impedance spectroscopy
    • radionuclide-based assays
  • implementation of suitable cell culture models for specific tumour targeting
  • establishment of stem cell-based 3D cell culture models (e. g. organoids)
  • proof of cellular uptake and subcellular distribution
  • release, recovery and activity studies of incorporated ingredients
  • drug screening, vascularization studies and cytotoxicity studies at HET-CAM system (Hen` s Egg Test on chorioallantoic membrane)
  • portfolio of cell lines and primary cell-based models for nanotoxicological studies
  • cytotoxicity studies according to ISO 10993/EN 30993
  • radionuclide-based and immunological assays

Production of nanoparticular transport systems

  • Production of biocompatible protein- and polymer-based nanoparticular transport systems for e. g., RNA, DNA, proteins or drugs
  • modification of nanoparticles with e. g., antibodies, peptides or polymers
  • physicochemical characterization of colloidal and nanoparticular formulations


REACH – Toxicological assessment by international standards

  • Assessment of the toxic potential of nanomaterials, chemicals, new materials and medical products
    • toxicological standard assessment according to REACH-test procedures (EG 440/2008)
    • acute & sub-chronic toxicity studies according to international standards (ISO, OECD)
    • studies for genotoxicity, neurotoxicity, cancerogenity, mutagenity
    • cytotoxicity studies (according to ISO 10993-5) and immunotoxicological assessment
    • vascularization test (HET-CAM assay) (Hen` s Egg Test on chorioallantoic membrane)
    • 3R alternatives to animal studies
      • reporter cell-based assays
      • single cell-based assays
      • miniaturized cell-based assays
      • radionuclide-based assays
      • individually developed assays
    • microchip-based toxicity studies
    • physicochemical characterization of (nano)materials and degradation products
    • portfolio of cell line- and primary cell-based models for (nano)toxicological studies

Route of entry of nanoparticles in the organism

  • Investigation of human and ecotoxicological exposure scenarios
    • In-vitro-/ex-vivo-exposure at air-liquid-interfaces (e. g., lung barrier, skin barrier) and at liquid-liquid-interfaces (e. g., intestinale barrier, blood-brain-barrier)
    • In-vitro-and ex-vivo studies of human toxicological effects in the low dose rangeproof of cellular uptake and the sub-cellular distribution in vitro
    • flow cytometry (FACS)
    • confocal Laser-Scanning-Microscopy (CLSM)
    • development of analytical tools for sensitive determination of the environmental fate and characteristics of nanomaterials in low dose range
    • ecotoxicological studies
    • microchip-based systems for cell cultivation and cell analysis
    • 3D, primary, multi cell models, tissue models (e. g. liver)
    • nanotoxicity, chemicals, drug screening
    • compatibility studies of medical products
    • alternative test systems for nanotoxicity studies

Equipment of the Department of Bioprocessing & Bioanalytics

Brochure of Main Department of Medical Biotechnology

Product Information Sheets of the Main Department of Medical Biotechnology

Projects of the Main Department of Medical Biotechnology

All Publications of the Main Department of Medical Bioechnology

Press Releases of the Main Department of Medical Biotechnology

Student Works in the Main Department of Medical Biotechnology